Febril Nötropeni
Özet
Febril nötropeni, kemoterapi alan hastalarda halen mortalite ve morbiditenin en önemli sebebidir. Günümüzde kemoterapi rejimlerindeki gelişmeler, hematopoietik kök hücre nakli/kemik iliği nakli merkezlerinin yaygınlaşması ile birlikte maligniteli çocuk olgularının sağ kalımı artmış, bununla birlikte febril nötropeni ataklarında artış yaşanmıştır. Bu da, febril nötropenili hastaların takibi ve standardizasyonu için başta IDSA ve European Conference on Infections in Leukaemia (ECIL) gibi uluslararası rehberler ve birçok ulusal rehberlerin geliştirilmesine yol açmıştır. Febril nötropeni ataklarının, risk faktörlerinin, olası etiyolojik etkenlerin bilinmesi, mümkün olan en kısa zamanda gerekli antibakteriyel antifungal ve antiviral tedavilerin düzenlenmesi, mortalite ve morbiditenin azaltılmasında en önemli basamağı oluşturmaktadır.
Referanslar
Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 2018 Aug 31;67(6):e1-e94.
Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018 May 10;36(14):1443-1453.
Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 Feb 15;52(4):e56-93.
Zimmer AJ, Freifeld AG: Optimal management of neutropenic fever in patients with cancer. J OncolPract15:19-24, 2019
Alali M, David MZ, Danziger-Isakov LA et al. Pediatric Febrile Neutropenia: Change in Etiology of Bacteremia, Empiric Choice of Therapy and Clinical Outcomes. J Pediatr Hematol Oncol. 2020 Aug;42(6):e445-e451
Ören H, Karakaş Z, Meral Güneş A et al. TPHD Eğitim Serisi I - Pediatrik Febril Nötropeni. İstanbul: Galenos; 2016. p. 15
El-Mahallawy HA, El-Wakil M, Moneer MM et al. Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer 2011;57(2):283-8
Palazzi DL. The use of antimicrobial agents in children with fever during chemotherapy-induced neutropenia: the importance of risk stratification. Pediatr Infect Dis J 2011;30(10): 887-90.
Ramphal R. Changes in the Etiology of Bacteremia in Febrile Neutropenic Patients and the Susceptibilities of the Currently Isolated Pathogens. Clin Infect Dis. 2004, s25–31
10.Davis K, Wilson S. Febrile neutropenia in paediatric oncology. Paediatric sand Child Health. 2020;30(3):93-7
Hakim H, Flynn PM, Knapp KM, et al. Etiology and clinical course of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2009;31(9):623-9
Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin North Am 2009;27(3):525-44
Santolaya ME, Alvarez AM, Aviles CL et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. Pediatr Infect Dis J 2008; 27(6):538-43
Groll AH, Pana D, Lanternier F et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. The Lancet Oncology. 2021;22(6):e254-e69
Meena JP, Brijwal M, Seth R, et al. Prevalence and clinical outcome of respiratory viral infections among children with cancer and febrile neutropenia. Pediatric hematology and oncology. 2019;36(6):330-43
Lee NH, Kang JM, Lee JW et al. Cefepime versus cefepime plu samikacin as an initial antibiotic choice for pediatric cancer patients with febrile neutropenia in an era of increasing cefepime resistance. The Pediatric Infectious Disease Journal. 2020;39(10):931-6.
Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipient. Journal of clinical oncology 2017.
Pulcini CD, Lentz S, Saladino RA et al. Emergency management of fever and neutropenia in children with cancer: A review. The American Journal of Emergency Medicine. 2021;50:693-8.
Ostrosky-Zeichner L, Alexander BD, Kett DH et al. Multicenter clinical evaluation of the (1-3) beta-D glucanassay as an aidto diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41(5):654-9.
Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340(10):764-71.
Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004;351(14):1391-402.
Cordonnier C, Pautas C, Maury S et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48(8): 1042-51
Pagano L, Caira M, NosariA,et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica 2011;96(9): 1366-70.
Goldberg E, Gafter-Gvili A, Robenshtok E, et al. Empirical antifungal therapy for patients with neutropenia and persistent fever: Systematic review and meta-analysis. Eur J Cancer 2008;44(15):2192-203
Kanda Y, Yamamoto R, Chizuka A, et al. Prophylacticaction of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000;89(7): 1611-25.
Walsh TJ, Pappas P, Winston DJ, et al.;National Institute of Allergy and Infectious Diseases Mycoses Study Group. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346(4):225-34
Hope WW, Castagnola E, Groll AH, et al; ESCMID Fungal Infection Study Group. ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candidas pp. Clin Microbiol Infect 2012;18(7):38-52
